Harbin Fuerjia Technology Development Co., Ltd. completed the acquisition of Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd..
March 28, 2021
Share
Harbin Fuerjia Technology Development Co., Ltd. agreed to acquire Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. (SZSE:002900) for CNY 570 million on February 9, 2021. As of December 31, 2020, has total assets of CNY 3.5 million, net assets of CNY 3.5 million, operating revenue of CNY 360.3 illion, operating profit of CNY 101.7 million and net profit of CNY 76.2 million.
Harbin Fuerjia Technology Development Co., Ltd. completed the acquisition of Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. (SZSE:002900) on March 1, 2021. The transaction was approved by the 9th meeting of the 3rd Directorate and the 2nd extraordinary shareholders meeting of 2021 of Harbin Medisan Pharmaceutical Co., Ltd.
HARBIN MEDISAN PHARMACEUTICAL CO LTD is a China-based company principally engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients (APIs), medical devices and cosmetics. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The Company's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The Company mainly distributes its products within domestic market.
HARBIN MEDISAN PHARMACEUTICAL CO., LTD. 
